BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25354978)

  • 1. TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells.
    Wang Q; Xu Z; An Q; Jiang D; Wang L; Liang B; Li Z
    Mol Med Rep; 2015 Feb; 11(2):982-8. PubMed ID: 25354978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of TAZ on human dental pulp stem cell proliferation and migration.
    Tian S; Tian X; Liu Y; Dong F; Wang J; Liu X; Zhang Z; Chen H
    Mol Med Rep; 2017 Jun; 15(6):4326-4332. PubMed ID: 28487958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
    Li Z; Wang Y; Zhu Y; Yuan C; Wang D; Zhang W; Qi B; Qiu J; Song X; Ye J; Wu H; Jiang H; Liu L; Zhang Y; Song LN; Yang J; Cheng J
    Mol Oncol; 2015 Jun; 9(6):1091-105. PubMed ID: 25704916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP and TAZ are distinct effectors of corneal myofibroblast transformation.
    Muppala S; Raghunathan VK; Jalilian I; Thomasy S; Murphy CJ
    Exp Eye Res; 2019 Mar; 180():102-109. PubMed ID: 30578787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.
    Anorga S; Overstreet JM; Falke LL; Tang J; Goldschmeding RG; Higgins PJ; Samarakoon R
    FASEB J; 2018 May; 32(5):2644-2657. PubMed ID: 29298862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells.
    Hiemer SE; Szymaniak AD; Varelas X
    J Biol Chem; 2014 May; 289(19):13461-74. PubMed ID: 24648515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β1 regulates the expression and transcriptional activity of TAZ protein via a Smad3-independent, myocardin-related transcription factor-mediated mechanism.
    Miranda MZ; Bialik JF; Speight P; Dan Q; Yeung T; Szászi K; Pedersen SF; Kapus A
    J Biol Chem; 2017 Sep; 292(36):14902-14920. PubMed ID: 28739802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma.
    Xiao H; Jiang N; Zhou B; Liu Q; Du C
    Cancer Sci; 2015 Feb; 106(2):151-9. PubMed ID: 25495189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of transcriptional coactivator TAZ in gliomas.
    Li W; Dong S; Wei W; Wang G; Zhang A; Pu P; Jia Z
    Oncotarget; 2016 Dec; 7(50):82686-82699. PubMed ID: 27764783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
    Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP/TAZ regulates TGF-β/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts.
    Qin Z; Xia W; Fisher GJ; Voorhees JJ; Quan T
    Cell Commun Signal; 2018 Apr; 16(1):18. PubMed ID: 29695252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Runx2/Smad3 complex negatively regulates TGF-β-induced connective tissue growth factor gene expression in vascular smooth muscle cells.
    Ohyama Y; Tanaka T; Shimizu T; Matsui H; Sato H; Koitabashi N; Doi H; Iso T; Arai M; Kurabayashi M
    J Atheroscler Thromb; 2012; 19(1):23-35. PubMed ID: 21986102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-β.
    Wang M; Liu Y; Zou J; Yang R; Xuan F; Wang Y; Gao N; Cui H
    Oncotarget; 2015 Apr; 6(11):9517-30. PubMed ID: 25940705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin.
    Yang N; Morrison CD; Liu P; Miecznikowski J; Bshara W; Han S; Zhu Q; Omilian AR; Li X; Zhang J
    Cell Cycle; 2012 Aug; 11(15):2922-30. PubMed ID: 22825057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of miR-153 inhibiting migration, invasion and epithelial-mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF-β) signaling pathway.
    Wang J; Liang S; Duan X
    J Cell Biochem; 2019 Jun; 120(6):9539-9546. PubMed ID: 30525231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNF111/Arkadia is regulated by DNA methylation and affects TGF-β/Smad signaling associated invasion in NSCLC cells.
    Chen H; Yang T; Lei Z; Wang L; Yang H; Tong X; Yang WT; Zhao J; Gu Y; Chen Y; Zhang HT
    Lung Cancer; 2015 Oct; 90(1):32-40. PubMed ID: 26238425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.